Response to treatment · patients with schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
1 finding from 1 review
Risk for at least one adverse event per patient · patients with schizophrenia
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
1 finding from 1 review
Adverse effects ‐ death · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
Quetiapine showed no clear difference in global state No clinical significant response as defined by the… compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · patients with schizophrenia
1 finding from 1 review
Cognitive function · patients with schizophrenia
1 finding from 1 review
Adverse effects: unspecified extrapyramidal symptoms · patients with schizophrenia
Quetiapine probably leads to lower extrapyramidal effects compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Prolactin level Average level in ng/mL · patients with schizophrenia
1 finding from 1 review
Desired sedation ‐ ultra short term ‐ asleep at 12 hours · patients with schizophrenia
BENZODIAZEPINES showed no clear difference in desired sedation ‐ ultra short term ‐ asleep at 12 hours compared with ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
No clinically important response to treatment ‐ ultra short term (at 12 hours) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes no clinically important response to treatment ‐ ultra short term (at… compared with ANTIPSYCHOTICS (very low certainty).
2 findings from 1 review
No clinically important response to treatment ‐ short term · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes no clinically important response to treatment ‐ short term compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to adverse effects (overall tolerability… compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).
1 finding from 1 review